Zusammenfassung
Die juvenile Psoriasis-Arthritis (JPsA) stellt eine Subform der juvenilen idiopathischen Arthritis dar, welche seit mehr als 15 Jahren auch in den pädiatrischen Klassifikationskriterien der ILAR definiert wird. Da die Arthritis bei Kindern häufig vor Psoriasis-Läsionen auftritt, ist das frühe Erkennen dieser Subform der Arthritis aufgrund weiterer Kriterien wie Daktylitis, Nagelveränderungen oder Familienanamnese zielführend. In diesem Beitrag werden ausführlich die Entwicklung der Klassifikationskriterien und die Bemühungen zur frühzeitigen Diagnostik der juvenilen Psoriasis-Arthritis zusammengefasst. Zur Ursache der Erkrankung ist noch wenig bekannt, in den letzten Jahren wurde aber sehr viel zu genetischen Faktoren sowie zur Pathogenese und den beteiligten Zytokinen publiziert. Mit dem zunehmenden Verständnis der beteiligten Zytokine kommt gegenwärtig auch eine Vielzahl von neuen Wirksubstanzen in der Therapie der JPsA zum Einsatz; besonders vielversprechend sind hier die Gruppen der TNF-α-Inhibitoren, der T-Zell-Kostimulationsblocker sowie der gegen IL-12, IL-23, IL-17a und IL-17-Rezeptor gerichteten Wirkstoffe. Darüber hinaus werden derzeit Substanzen mit neuem Wirkprinzip, wie z. B. Phosphodiesterase-Inhibition oder Januskinase-lnhibition, hinsichtlich ihrer Wirksamkeit und Verträglichkeit bei der Therapie der juvenilen Psoriasis-Arthritis geprüft.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Abu-Shakra M, Gladman DD, Thorne JC et al (1995) Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22:241–245
Acosta Felquer ML, Coates LC, Soriano ER et al (2014) Drug therapies for peripheral joint disease in Psoriatic arthritis: a systematic review. J Rheumatol 41:2277–2285
Ansell BM, Rudge S, Schaller JG (1991) A colour atlas of paediatric rheumatology. Mosby-Wolfe, London
Behrens F, Finkenwirth C, Pavelka K et al (2013) Leflunomide in Psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res 65:464–470
Bernston L, Fasth A, Andersson-Gäre B et al (2001) Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population-based incidence study from the Nordic countries. J Rheumatol 28:2737–2743
Bowyer S, Roettcher P, members of the Pediatric Rheumatology Database Research Group (1996) Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J Rheumatol 23:1968–1974
Butbul YA, Tyrrell PN, Schneider R, Dhillon S et al (2009) Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they? J Rheumatol 36:2033–2041
Calabro JJ (1977) Psoriatic arthritis in children. Arthritis Rheum 20(Suppl):408–410
Chang JC, Smith LR, Froning KJ et al (1997) Persistence of T cell clones in psoriatic lesions. Arch Dermatol 133:703–708
Cline A, Bartos GJ, Strowd LC, Feldman SR (2019) Biologic treatment options for pediatric psoriasis and atopic dermatitis. Children (Basel) 6(9):103
Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis: treatment recommendations for psoriatic arthritis. Arthritis Rheum. https://doi.org/10.1002/art39573
Consolaro A, Giancane G, Alongi A et al (2019) Paediatric Rheumatology International Trials Organisation. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health 3(4):255–263
Costello P, Bresnihan B, O’Farrelly C, Fitzgerald O (1999) Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 26:1117–1124
Cuellar ML, Espinoza LR (1997) Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 23:797–809
Day TG, Ramanan AV, Hinks A et al (2008) Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum 58:2142–2146
Eldar JT, Henseler T, Christophes E et al (1994) Of genes and antigens. The genetics of psoriasis. J Invest Dermatol 1(Suppl):218–226
Eng SWM, Aeschlimann FA, van Veenendaal M, ReACCh-Out Research Consortium et al (2019) Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: a prospective study with multilayer non-negative matrix factorization. PLoS Med 16(2):e1002750
Espinoza LR, Zakkraoni L, Espinoza CG et al (1992) Psoriatic arthritis clinical response and side effects of methotrexate therapy. J Rheumatol 19:872–877
Fantini F (2001) Classification of chronic arthritides in childhood (juvenile idiopathic arthritis): criticisms and suggestions to improve the efficacy of the Santiago-Durban criteria. J Rheumatol 28:456–459
Farber EM, Nall L (1999) Childhood psoriasis. Cutis 64:309–314
Flato B, Lien G, Smerdel-Ramoya A et al (2009) Juvenile psoriatic arthritis: longterm outcome and differentiation form other subtypes of juvenile idiopathic arthritis. J Rheumatol 36:642–650
Foeldvari I, Bidde M (2000) Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. J Rheumatol 27:1069–1072
Gare BA, Fasth A (1992) Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 90:950–958
Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13:586–592
Gladman DD, Farewell VT, Kopciuk A, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25:730–733
Glerup M, Rypdal V, Arnstad ED, Nordic Study Group of Pediatric Rheumatology et al (2020) Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken) 72(4):507–516
Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700–712
Gottlieb SL, Gilleaudeau P, Johnson R et al (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune but not keratinocyte, pathogenic basis. Nat Med 1:442–447
Harrison BJ, Silman AJ, Barrett EM et al (1997) Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol 24:1744–1749
Hinks A, Martin P, Flynn E et al (2011) Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthrit Res Therapy 13:R12
Hinks A, Bowes J, Cobb J, Ainsworth HC, Marion MC, Corneau MR et al (2017) Fine mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis 76:765–772
Hofer MF, Mouy R, Prieur A-M (2000) Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 28:1083
Huemer C, Malleson PN, Cabral DA et al (2002) Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. J Rheumatol 29:1531–1535
Hyrich KL, Lal SD, Foster HE et al (2010) Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 49(1):116–122
Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026
Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368–1377
Konig A, Krenn V, Gillitzer R et al (1997) Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis- an immunohistochemical and mRNA analysis. Rheumatol Int 17:159–168
Krumrey-Langkammerer M, Hafner R (2002) Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 28:2544–2547
Landells I, Marano C, Hsu MC et al (2015) Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 73(4):594–603
Langevitz P, Buskila D, Gladman DD (1990) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 17:695–697
Lee EY, Sundel RP, Kim S et al (2008) MRI findings of juvenile psoriatic arthritis. Skeletal Radiol 37:987–996
Li SJ, Perez-Chada LM, Merola JF (2019) TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis 4(2):70–80
Malleson PN, Fung MY, Rosenberg AM (1996) The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 23:1981–1987
Manners P, Lesslie J, Speldewinde D, Tunbridge D (2003) Classification of juvenile idiopathic arthritis: should family history be included in the criteria? J Rheumatol 30:8
Marrakchi S, Guigue P, Renshaw BR et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365(7):620–628
Marsal S, Armadens-Gil L, Martinez M et al (1999) Clinical radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology 38:332–337
Martini A, Ravelli A, Avcin T, Pediatric Rheumatology International Trials Organization (PRINTO) et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 46(2):190–197
McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active Psoriatic arthritis: 1 year results of the phase 3 multicenter double blind placebo controlled PSUMMIT trial. Lancet 382:780–789
McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-inerleukin-17 A monoclonal antibody, in patients with Psoriatic arthritis (FUTURE2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137–1146
Mease P, Hall S, FitzGerald O et al (2017) Tofacitinib or Adalimumab versus Placebo for psoriatic arthritis. N Engl J Med 377(16):1537–1550
Michalek IM, Loring B, John SM (2017) A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 31(2):205–212
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55
Murray KJ, Grom AA, Thompson SD et al (1998) Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondylarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25:1388–1398
Nash P, Thaci D, Behrens F et al (2006) Leflunomide improves Psoriasis in patients with Psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212:238–249
Nickoloff BJ, Mitra RS, Sailer D et al (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820–828
Nigrovic PA, Raychaudhuri S, Thompson SD (2018) Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol 70(1):7–17
Oen K, Fast M, Postl B (1995) Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975–1992: cycles in incidence. J Rheumatol 22:820–828
Partsch G, Wagner E, Leeb BF et al (1998) Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25:105–110
Paukkonnen K, Naukkarinen A, Horstmanheimo M (1992) The development of manifest psoriatic lesions is linked with the invasion of CD8+ cells and CD11c+ macrophages into the epidermis. Arch Dermatol Res 284:375–379
Petty RE, Southwood TR, Baum J et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 25:10
Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 31:2
Punzi L, Pianon M, Bertazzolo N et al (1998) Clinical laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin Exp Rheumatol 16:277–281
Ramsey SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE (2000) Comparison of criteria for the classification of childhood arthritis. J Rheumatol 27:5
Ravelli A, Consolaro A, Horneff G et al (2018) Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 77(6):819–828
Reece RJ, Canete JD, Parsons WJ et al (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 42:1481–1484
Ritchlin C, Hass-Smith SA, Hicks D et al (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544–1552
Roberton DM, Cabral DA, Malleson PN, Petty RE (1996) Juvenile psoriatic arthritis: follow-up and evaluation of diagnostic criteria. J Rheumatol 23:166–170
Salvarani C, Cantini F, Olivieri I et al (1997) Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol 24:1106–1110
Selvaag AM, Aulie HA, Lilleby V, Flatø B (2016) Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 75(1):190–195
Southwood TR, Petty RE, Malleson PN et al (1989) Psoriatic arthritis in children. Arthritis Rheum 32:1007
Sticherling M, Minden K, Küster RM et al (2007) Psoriasis und Psoriasisarthritis im Kindes – und Jugendalter. Z Rheumatol 66(4):349–354
Stoll ML, Mellins ED (2020) Psoriatic arthritis in childhood: a commentary on the controversy. Clin Immunol 214:108396
Stoll ML, Nigrovic PA (2011) Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol 29:582–588
Stoll ML, Zurakowksi D, Nigrovic LR, Nichols DP et al (2006) Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 54:3564–3572
Stoll ML, Lio P, Sundel RP et al (2008) Comparison of Vancouver and ILAR classification criteria for juvenile psoriatic arthritis. Arthritis Rheum 59:51–58
Symmons DPM, Jones M, Osborne J et al (1996) Pediatric rheumatology in the United Kingdom: data from the British Paediatric Rheumatology Group National Diagnostic Register. J Rheumatol 23:1975–1980
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2655–2673
Telfer NR, Chalmers RJ, Whale K, Colman G (1992) The role of streptococcal infection in the initiation of Guttate psoriasis. Arch Dermatol 128:39–42
Tomfohrde J, Silverman A, Barnes R et al (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264:1141–1145
Vasey FB, Deitz C, Fenske NA et al (1982) Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol 9:719–722
Vasey FB, Seleznick MJ, Fenske NA, Espinoza LR (1989) New sign-posts on the road to understanding psoriatic arthritis. J Rheumatol 16:1405–1407
Wong WM, Howell WM, Coy SD et al (1996) Interleukin-2 is found in the synovium of psoriatic arthritis and spondyloarthritis, not in rheumatoid arthritis. Scand J Rheumatol 25:239–245
Zisman D, Gladman DD, Stoll ML et al (2017) The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification and outcomes. J Rheumatol 44(3):342–351
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Huemer, C., Minden, K. (2022). Juvenile Psoriasisarthritis. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60410-6_30
Download citation
DOI: https://doi.org/10.1007/978-3-662-60410-6_30
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60409-0
Online ISBN: 978-3-662-60410-6
eBook Packages: Medicine (German Language)